# Alumis Inc. (ALMS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $11.10, market value $1.4 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Alumis Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 194.2×**. Each dollar of revenue is priced at 194.2×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 3.2×**. The shares trade at 3.2× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -24.5%** (5-yr avg -79.9%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -80.8%**. Return on equity is negative because earnings are negative.
- **Return on assets: -106.6%**. Each dollar of assets produces -106.6% of profit.

## Growth
- **EPS growth (1 yr): 72.4%**. Earnings per share rose 72.4%.

## Financial health
- **Current ratio: 4.34** (quick 4.34). Current assets cover the next year's liabilities 4.34 times.
- **Altman Z-score: 5.95**. A Z-score of 5.95 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Alumis Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (9 analysts). 9 analysts cover Alumis Inc.; the consensus is strong_buy, with an average price target of $40.33 (+263% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 141.3%** (YTD 13.7%, 3-mo -41.8%). The shares are up 141.3% over twelve months including dividends.
- **From 52-week high: -64.6%** (195.2% above the low). Trading 65% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 23**. An RSI of 23 is oversold; bounces are common, but oversold can stay oversold in a real decline.
- **Beta (1 yr): 1.74** (volatility 135%). Beta of 1.74 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ALMS · Page: https://foliofundamentals.com/stocks/alms

Not investment advice.